Brokerages forecast that Audentes Therapeutics, Inc. (NASDAQ:BOLD) will announce earnings per share of ($0.82) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Audentes Therapeutics’ earnings. The highest EPS estimate is ($0.80) and the lowest is ($0.83). Audentes Therapeutics reported earnings per share of ($0.94) in the same quarter last year, which would indicate a positive year-over-year growth rate of 12.8%. The company is scheduled to report its next earnings report on Thursday, November 9th.

On average, analysts expect that Audentes Therapeutics will report full-year earnings of ($3.55) per share for the current fiscal year, with EPS estimates ranging from ($4.12) to ($3.21). For the next fiscal year, analysts forecast that the company will report earnings of ($3.81) per share, with EPS estimates ranging from ($5.98) to ($2.88). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Audentes Therapeutics.

Audentes Therapeutics (NASDAQ:BOLD) last posted its earnings results on Thursday, August 10th. The biotechnology company reported ($0.87) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.77) by ($0.10).

Several research firms have recently issued reports on BOLD. Zacks Investment Research cut shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 8th. Evercore ISI began coverage on shares of Audentes Therapeutics in a research report on Wednesday, August 16th. They set an “outperform” rating and a $23.00 price objective on the stock. ValuEngine upgraded shares of Audentes Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, July 20th. Raymond James Financial, Inc. began coverage on shares of Audentes Therapeutics in a research report on Thursday. They set a “market perform” rating on the stock. Finally, Bank of America Corporation reiterated a “buy” rating and set a $33.00 price objective (up previously from $23.00) on shares of Audentes Therapeutics in a research report on Friday, September 22nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $24.17.

In related news, major shareholder Orbimed Advisors Llc sold 672,000 shares of the firm’s stock in a transaction on Friday, September 29th. The shares were sold at an average price of $28.25, for a total value of $18,984,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP David Nagler sold 3,750 shares of the firm’s stock in a transaction on Wednesday, September 27th. The shares were sold at an average price of $30.00, for a total transaction of $112,500.00. Following the completion of the transaction, the senior vice president now directly owns 3,750 shares of the company’s stock, valued at $112,500. The disclosure for this sale can be found here. Over the last three months, insiders sold 766,500 shares of company stock valued at $21,443,730. 47.30% of the stock is currently owned by insiders.

Hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN grew its holdings in shares of Audentes Therapeutics by 278.5% in the first quarter. Wells Fargo & Company MN now owns 7,747 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 5,700 shares in the last quarter. Nationwide Fund Advisors grew its holdings in shares of Audentes Therapeutics by 288.9% in the second quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock valued at $164,000 after purchasing an additional 6,384 shares in the last quarter. Citadel Advisors LLC purchased a new position in shares of Audentes Therapeutics in the first quarter valued at $184,000. State of Wisconsin Investment Board purchased a new position in shares of Audentes Therapeutics in the second quarter valued at $210,000. Finally, Rhumbline Advisers purchased a new position in shares of Audentes Therapeutics in the second quarter valued at $252,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/13/audentes-therapeutics-inc-bold-expected-to-post-earnings-of-0-82-per-share.html.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Get a free copy of the Zacks research report on Audentes Therapeutics (BOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.